Consent pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Servier Laboratories Australia

Overview

The Therapeutic Goods Act 1989 was enacted by the Australian Parliament to regulate the quality, safety, efficacy and timely availability of therapeutic goods in Australia. This legislation provides a regulatory framework that ensures therapeutic goods, including medicines, medical devices, and blood and blood components, meet acceptable standards. The Therapeutic Goods Administration (TGA), a department within the Australian Government's Department of Health, administers this Act to protect public health by regulating the supply and advertising of therapeutic goods. In the context of the consent notice, the Act allows the TGA to grant exceptions under certain circumstances to ensure that therapeutic goods that are necessary for the health of the Australian public are available, while still maintaining the overall safety and quality standards. The policy objective is to balance public health needs with regulatory requirements, ensuring that therapeutic goods that meet the necessary standards are accessible to those who need them.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of therapeutic goods, including medicines, medical devices, and blood and blood components, and regulates their supply, import, export, and advertising in Australia. This federal legislation governs the quality, safety, and efficacy of therapeutic goods, ensuring they meet the necessary standards for public health and safety. The Act applies to individuals, companies, and other entities involved in the supply of therapeutic goods within the Australian jurisdiction. Subordinate instruments, such as Therapeutic Goods Orders (TGOs), extend and detail the application of the Act by providing specific regulations for different categories of therapeutic goods. In the context of the consent provided by the Therapeutic Goods Administration for the importation and supply of certain perindopril erbumine products that do not conform with labelling requirements, the Act allows for specific exceptions under certain conditions. These exceptions are limited to the specified batches and are subject to conditions, including the distribution of a 'Dear Pharmacist' letter to ensure patients are informed about the correct labelling. This demonstrates how the Act provides flexibility to address specific issues while maintaining stringent controls over the therapeutic goods market.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides the framework for regulating therapeutic goods in Australia. Sections 14 and 14A of the Act allow the Secretary of the Department of Health to consent to the importation and supply of therapeutic goods that do not fully comply with the relevant standards or requirements, under certain conditions. This was applied in the case of Servier Laboratories Australia Pty Ltd, where consent was granted to import and supply certain batches of perindopril erbumine tablets that did not meet the labelling requirements of the Therapeutic Goods Order No. 69 – General requirements for labels for medicines (TGO 69). Specifically, these tablets did not have the appropriate prefixes before the batch and expiry details on the blister packs. This consent was issued to ensure that patients could still receive necessary medication while mitigating any potential risks associated with the non-compliance. The consent imposed specific obligations on Servier Laboratories Australia Pty Ltd to ensure patient safety and compliance with regulatory requirements. Firstly, a 'Dear Pharmacist' letter (referred to as TRIM reference R15/596764) had to be included with each affected batch. This letter contained text provided to the Therapeutic Goods Administration and served to remind pharmacists to ensure that patients keep the blister packs with the correctly labelled carton. This measure aimed to prevent any confusion or potential harm arising from the labelling discrepancies. Breaching the conditions of the consent or failing to comply with the imposed obligations can lead to serious consequences. Under the Act, non-compliance with the specified conditions can result in criminal charges, including fines and imprisonment. The specific penalties are not detailed in the consent notice but generally, contraventions of the Therapeutic Goods Act can incur substantial penalties, reflecting the seriousness of ensuring the safety and quality of therapeutic goods in Australia. For instance, individuals found guilty of supplying non-compliant therapeutic goods may face fines of up to $220,000 and/or imprisonment for up to five years. Companies may face even higher penalties, with fines potentially reaching up to $1.1 million for serious offences. Such stringent measures underscore the importance of adhering to the conditions set forth by the Therapeutic Goods Administration to protect public health.